xanomeline – Talk Bio

Actionable Insights Powered by AI

Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action

10 months ago talkbio0Tagged Antipsychotic Agents, Approved, Cobenfy, Muscarinic Acetylcholine Receptor, Myers, Schizophrenia, squibb, trospium chloride, United States Food and Drug Administration, xanomeline

Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.